Xifaxan and Failure to thrive - a phase IV clinical study of FDA data

Summary:

Failure to thrive is reported as a side effect among people who take Xifaxan (rifaximin), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Humira, and have Crohn's disease.

The phase IV clinical study analyzes which people have Failure to thrive when taking Xifaxan. It is created by eHealthMe based on reports of 16,409 people who have side effects when taking Xifaxan from the FDA, and is updated regularly.

What is Xifaxan?

Xifaxan has active ingredients of rifaximin. It is often used in irritable bowel syndrome. eHealthMe is studying from 16,609 Xifaxan users. Check the latest studies of Xifaxan.

What is Failure to thrive?

Failure to thrive (inadequate weight gain and physical growth in children) is found to be associated with 769 drugs and 1,168 conditions by eHealthMe. Check the latest studies of Failure to thrive.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

16,409 people reported to have side effects when taking Xifaxan.
Among them, 12 people (0.07%) have Failure to thrive.

Among these 12 people:

How long have people been on Xifaxan when they have Failure to thrive? *

What is the gender of people who have Failure to thrive when taking Xifaxan? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Failure to thrive when taking Xifaxan? *

What are other drugs people take besides Xifaxan? *

What are other side effects people have besides Failure to thrive? *

Abdominal Distension: 4 people, 33.33%
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking): 4 people, 33.33%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 25.00%
Dehydration (dryness resulting from the removal of water): 3 people, 25.00%
Diarrhea: 3 people, 25.00%
Pain: 3 people, 25.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 3 people, 25.00%
Abdominal Pain: 2 people, 16.67%
Colitis (inflammation of colon): 2 people, 16.67%
Confusional State: 2 people, 16.67%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 2 people, 16.67%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 2 people, 16.67%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 16.67%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 8.33%
Small Intestinal Bacterial Overgrowth: 1 person, 8.33%
Pancreatitis Chronic (chronic inflammation of pancreas): 1 person, 8.33%
Dyspnea (difficult or laboured breathing): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Xifaxan and have Failure to thrive?

- Check whether Failure to thrive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xifaxan:

Xifaxan (16,609 reports)

Browse all side effects of Xifaxan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Failure to thrive:

Failure to thrive (769 drugs)

Browse all the conditions that are associated with Failure to thrive:

Failure to thrive (1,168 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rifaximin (the active ingredients of Xifaxan) and Xifaxan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.